Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus

This article was originally published in The Pink Sheet Daily

Executive Summary

A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.

You may also be interested in...



Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva

German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.

Where Merck KGAA’s Pipeline Stands

Pipeline review resulted in new focus and products with high value, exec explains.

Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal

Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel